A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
As an early event in the viral life cycle, the entry of enveloped viruses into target cells has received considerable attention. Viral fusion to cellular targets has been studied principally with fusion assays in which cells engineered to express the viral envelope are cultured with the target cells. These assays yield valuable information but do not fully recapitulate all of the variables governing the fusion of actual virions to their cellular targets. The virion membrane and the plasma membrane, for example, differ strikingly in their lipid and protein compositions. Two virion-based fusion assays have been described. One is based on the redistribution of a self-quenching fluorophore, whereas the second depends on photosensitized activation of a hydrophobic probe by a fluorescent lipid loaded into the target membrane. These assays are complex and have not been adapted to study fusion in complex cell populations. We have developed a simple, rapid assay allowing the detection of HIV-1 virion fusion to biologically relevant target cells, including primary CD4(+) T lymphocytes. It is based on the incorporation of beta-lactamase-Vpr chimeric proteins (BlaM-Vpr) into HIV-1 virions and their subsequent delivery into the cytoplasm of target cells as a result of virion fusion. This transfer is then detected by enzymatic cleavage of the CCF2 dye, a fluorescent substrate of beta-lactamase (BlaM), loaded in the target cells. BlaM cleaves the beta-lactam ring in CCF2, changing its fluor…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nguyen, D. H., & Hildreth, J. E. K. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3264-3272.2000 · Cited by 788
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751 · cited 1×
“Conversely, no shift to increased blue fluorescence was observed in these CCR5-Jurkat T cells when the culture was preincubated with 250 nM TAK-779, an inhibitor of CCR5-dependent entr”
BackgroundZlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K., & Tsien, R. Y. (1998) · Science · doi:10.1126/science.279.5347.84 · Cited by 690
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554 · cited 1×
“Consistent with this color change deriving from the fusion of virions to the target cells, essentially no blue cells were detected in virally infected HeLa-CD4 cells pretreated with 250 nM AMD3100, an inhibitor of CXCR4-dependent viral entr”
BackgroundAloia, R. C., Tian, H., & Jensen, F. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5181 · Cited by 440
Nussbaum, O., Broder, C. C., & Berger, E. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5411-5422.1994 · Cited by 338
Dynamic Disruptions in Nuclear Envelope Architecture and Integrity Induced by HIV-1 Vpr
de Noronha, C. M. C., Sherman, M. P., Lin, H. W., Cavrois, M. V., Moir, R. D., Goldman, R. D., & Greene, W. C. (2001) · Science · doi:10.1126/science.1063957 · Cited by 276 · cited 1×
“1-BlaM into the Hin dIII site of pCMV4-HA-Vpr (ref”
MethodSelf-citationHIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues
Eckstein, D. A., Penn, M. L., Korin, Y. D., Scripture-Adams, D. D., Zack, J. A., Kreisberg, J. F., Roederer, M., Sherman, M. P., Chin, P. S., & Goldsmith, M. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00217-5 · Cited by 232
Bridger, G. J., Skerlj, R. T., Thornton, D., Padmanabhan, S., Martellucci, S. A., Henson, G. W., Abrams, M. J., Yamamoto, N., & Vreese, K. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00002a019 · Cited by 209
Cytosolic Gag p24 as an Index of Productive Entry of Human Immunodeficiency Virus Type 1
Maréchal, V., Clavel, F., Heard, J. M., & Schwartz, O. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2208-2212.1998 · Cited by 207 · cited 1×
“However, in the absence of appropriate viral receptors in the vesicles, this entry pathway does not lead to productive infectio”
Background
Cited by
Items 301–400 of 490
Spillings, B. L., Day, C. J., Minambres, A. G., Aggarwal, A., Condon, N. D., Haselhorst, T., Purcell, D. F. J., Turville, S. G., Stow, J. L., Jennings, M. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110296 · Cited by 23
Durham, N. D., & Chen, B. K. (2015) · Journal of Virology · doi:10.1128/jvi.00655-15 · Cited by 22
“Donor Jurkat cells were nucleofected with WT or mutant NL4-3 plasmid DNA, as well as the plasmid pMM310 (61, 62), which encodes the -lactamase (BlaM)–Vpr fusion protein (ARP; catalog no.”
MethodWang, J., Kondo, N., Long, Y., Iwamoto, A., & Matsuda, Z. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.06.017 · Cited by 22
“A quantitative fusion assay using enzymes, either as prexpressed self-complementing enzyme fragments or as induced eporter enzymes, requires the addition of enzyme substrates to onitor the processes (Cavrois et al., 2002; Holland et al., 2004; Jun nd Wickner, 2007).”
Erratum: Efficient delivery of lentiviral vectors into resting human CD4 T cells
Geng, X., Doitsh, G., Yang, Z., Galloway, N. L. K., & Greene, W. C. (2016) · Gene Therapy · doi:10.1038/gt.2015.115 · Cited by 22
Self-citationTLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes
Hofmann, H., Vanwalscappel, B., Bloch, N., & Landau, N. R. (2016) · Retrovirology · doi:10.1186/s12977-016-0316-3 · Cited by 23
Labib, M., Shipman, P. O., Martić, S., & Kraatz, H. (2011) · Electrochimica Acta · doi:10.1016/j.electacta.2011.03.063 · Cited by 21
Dendritic Cells Enhance HIV Infection of Memory CD4 + T Cells in Human Lymphoid Tissues
Reyes-Rodríguez, Á. L., Reuter, M. A., & McDonald, D. J. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0235 · Cited by 21
“The use of CXCR4-tropic HIV has become predominant when tonsillar cultures are used as a model of HIV infection.(24,33-37) Infections were performed in the absence or presence of labeled, LPS activated MDDCs and analyzed 3 days later by fluorescence microscopy.”
Esposito, A. M., Cheung, P., Swartz, T. H., Li, H., Tsibane, T., Durham, N. D., Basler, C. F., Felsenfeld, D. P., & Chen, B. K. (2016) · Virology · doi:10.1016/j.virol.2015.10.013 · Cited by 20
“A practical example of this type of assay utilizes the beta-lactamase (Blam) reporter gene fused to HIV Vpr, which is efficiently packaged into virus particles and then delivered into target cells upon virus fusion (Cavrois et al., 2002).”
BackgroundMethodInfluentialPSGL-1 inhibits HIV-1 infection by restricting actin dynamics and sequestering HIV envelope proteins
Liu, Y., Song, Y., Zhang, S., Diao, M., Huang, S., Li, S., & Tan, X. (2020) · Cell Discovery · doi:10.1038/s41421-020-0184-9 · Cited by 20
Cole, M. S., Hegde, P. V., & Aldrich, C. C. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00315 · Cited by 20
The DEAD box RNA helicase DDX42 is an intrinsic inhibitor of positive‐strand RNA viruses
Bonaventure, B., Rebendenne, A., Valadão, A. L. C., Arnaud‐Arnould, M., Gracias, S., García-de-Gracia, F., McKellar, J., Labaronne, E., Tauziet, M., Vivet‐Boudou, V., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154061 · Cited by 22
“…on target cells. b -lactamase-Vpr (BlaM-Vpr)-carrying viruses, bearing the wild-type Env, were produced by co-transfection of HEK293T cells with the NL4-3/Nef-IRES-Renilla provirus expression vector, pBlaM-Vpr and pAdVAntage at a ratio of 4:1:0.5, as previously described (Cavrois et al , 2002).”
InfluentialHIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
Eissmann, K., Mueller, S., Sticht, H., Jung, S., Zou, P., Jiang, S., Gross, A., Eichler, J., Fleckenstein, B., & Reil, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054452 · Cited by 20
“The virion-based fusion assay was performed essentially as described elsewhere [41].”
MethodTait‐Burkard, C., Bloyet, L.-M., Wicht, O., van Kuppeveld, F. J. M., Rottier, P. J. M., de Haan, C. A. M., & Bosch, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101762 · Cited by 20
“Therefore either firefly-or gaussia luciferase, or b - lactamase have been incorporated as structural (lumenal) fusion proteins into virions [20–25].”
Mazurov, D. V., Ramadan, L., & Kruglova, N. A. (2023) · Viruses · doi:10.3390/v15030690 · Cited by 19
“lactam ring of the CCF2, changing its emission spectrum from green to blue [42].”
BackgroundLipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
Nieto‐Garai, J. A., Glass, B., Bunn, C., Giese, M., Jennings, G. S., Brankatschk, B., Agarwal, S., Börner, K., Contreras, F. ‐., Knölker, H., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01983 · Cited by 19
Terahara, K., Ishige, M., Ikeno, S., Mitsuki, Y.-Y., Okada, S., Kobayashi, K., & Tsunetsugu‐Yokota, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053495 · Cited by 20
“Fusion Assay A fusion assay was performed using HIV-1 possessing blactamase-Vpr chimeric proteins (BlaM-Vpr) and CD4 T cells loaded with CCF2 dye, a fluorescent substrate for b-lactamase, as previously described [31,32].”
MethodBourgeois, R., Mercier, J., Paquette-Brooks, I., & Cohen, É. A. (2006) · Retrovirology · doi:10.1186/1742-4690-3-31 · Cited by 23
“After infection with the BlaM-Vpr-containing virions, A201 cells were loaded with the CCF2-AM dye, a fluorescent substrate of BlaM, as previously described [16].”
MethodAn expanded model of HIV cell entry phenotype based on multi-parameter single-cell data
Bożek, K., Eckhardt, M., Sierra, S., Anders‐Össwein, M., Kaiser, R., Kräusslich, H., Müller, B., & Lengauer, T. (2012) · Retrovirology · doi:10.1186/1742-4690-9-60 · Cited by 18
de Sousa-Pereira, P., Abrantes, J., Bauernfried, S., Pierini, V., Esteves, P. J., Keppler, O. T., Pizzato, M., Hornung, V., Fackler, O., & Baldauf, H. (2018) · Journal of General Virology · doi:10.1099/jgv.0.001201 · Cited by 18
Deniger, D. C., Kolokoltsov, A. A., Moore, A. C., Albrecht, T., & Davey, R. A. (2006) · Nano Letters · doi:10.1021/nl061180z · Cited by 18
Singh, P., Pahari, P., Mukherjee, S., Karmakar, S., Hoffmann, M., Mandal, T., & Das, D. K. (2024) · mBio · doi:10.1128/mbio.01077-24 · Cited by 17
“2A) (Materials and Methods).”
MethodInfluentialCorleis, B., Lisanti, A. C., Körner, C., Schiff, A. E., Rosenberg, E. S., Allen, T. M., Altfeld, M. A., & Kwon, D. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173161 · Cited by 17
“We made use of the previously described Vpr-BLaM assay to detect frequency of early viral entry [40].”
MethodZhang, Y., de la Torre, J. C., & Melikyan, G. B. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010625 · Cited by 17
“Next, we examined the effect of ectopic hLAMP1 expression on the efficiency of LASVpp fusion with A549 and DF-1 cells using a direct virus-cell fusion assay that reports the delivery of virus-incorporated beta-lactamase (BlaM) into the cytoplasm [14,15].”
BackgroundWelman, M., Lemay, G., & Cohen, É. A. (2006) · Virus Research · doi:10.1016/j.virusres.2006.10.009 · Cited by 17
Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay
Pontow, S. E., Harmon, B., Campbell, N., & Ratner, L. (2007) · Virology · doi:10.1016/j.virol.2007.06.022 · Cited by 17
“It compares favorably with other assays of virus, such as one that depends upon transfer of a virus core containing a Vprβ-lactamase fusion protein into a target cell, which requires a longer incubation time and FACS analyses (Cavrois et al., 2004; Cavrois et al., 2002).”
MethodLewis, G., Christiansen, L., McKenzie, J., Luo, M., Pasackow, E., Smurnyy, Y. D., Harrington, S., Gregory, P. D., Veres, G., Nègre, O., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.001 · Cited by 18
“In this study, we found that pre-treatment of CD34 cells with staurosporine prior to transduction led to an approximate 2- to 3-fold increase in entry of LVV, as measured via the BlaM assay.(19) Investigation into the mechanism revealed that staurosporine treatment inhibits cofilin phosphorylation at serine 3, which l…”
MethodFernandez, M. V., Hoffman, H. K., Pezeshkian, N., Tedbury, P. R., van Engelenburg, S. B., & Freed, E. O. (2020) · Journal of Virology · doi:10.1128/jvi.01334-20 · Cited by 16
“Entry of BlaM-Vpr-containing virus was detected using a fluorescent substrate, CCF2-AM (Thermo Fisher, Cat# K1032) (94).”
MethodRestriction of Influenza A Virus by SERINC5
Lai, K. K., Munro, J. B., Shi, G., Majdoul, S., Compton, A. A., & Rein, A. R. (2022) · mBio · doi:10.1128/mbio.02923-22 · Cited by 16
“We tested the effect on virus-cell fusion using the b-lactamase-Vpr (BlaM-Vpr) fusion assay (26, 27).”
MethodMeasuring T Cell-to-T Cell HIV-1 Transfer, Viral Fusion, and Infection Using Flow Cytometry
Durham, N. D., & Chen, B. K. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3046-3_2 · Cited by 16
“pMM310 encodes the BlaM-Vpr fusion protein [34, 35] that packages the βlactamase Vpr fusion protein into virus particles when cotransfected with an HIV proviral plasmid, e.”
MethodSampah, M. E., Laird, G. M., Blankson, J. N., Siliciano, R. F., & Coleman, J. S. (2015) · AIDS · doi:10.1097/qad.0000000000000681 · Cited by 20
“Entry assay X4 and R5-tropic single-cycle, pseudoviruses that incorporate the enzyme b-lactamase fused to the viral accessory gene vpr were made as previously described [29].”
MethodGonelli, C. A., King, H. A. D., Mackenzie, C., Sonza, S., & Purcell, D. F. J. (2021) · Vaccines · doi:10.3390/vaccines9030239 · Cited by 16
“The viral fusion assays (originally based on published protocols [83]) were performed as described previously [57].”
InfluentialMaarifi, G., Lagisquet, J., Hertel, Q., Bonaventure, B., Chamontin, C., Fuchs, K. J., Moncorgé, O., Tauziet, M., Mombled, M., Papin, L., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106540 · Cited by 17
Target silencing of components of the conserved oligomeric Golgi complex impairs HIV-1 replication
Liu, S., Dominska-Ngowe, M., & Dykxhoorn, D. M. (2014) · Virus Research · doi:10.1016/j.virusres.2014.08.015 · Cited by 16
“To investigate whether the impairment in HIV-1 replication by lobe B factor silencing is before or after viral fusion, a fusion assay utilizing β-lactamase-Vpr chimeric proteins was performed (Cavrois et al., 2002; Cavrois et al., 2011).”
MethodMoreno‐Fernandez, M. E., Aliberti, J., Groeneweg, S., Köhl, J., & Chougnet, C. A. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0099 · Cited by 15
“After PMA treatment, transfected THP-1 cells were infected overnight with YK-JRCSF-BlaM-Vpr (MOI = 1).(27) The cells were then loaded with the CCF2-AM dye for 1 h and the fusion was measured 6 h later by flow cytometry.”
MethodMasters, A., Ogden, R., Wetton, J. H., & Dawnay, N. (2019) · Forensic Science International · doi:10.1016/j.forsciint.2019.05.041 · Cited by 15
Quantitative FRET-FLIM-BlaM to Assess the Extent of HIV-1 Fusion in Live Cells
Carlón-Andrés, I., & Padilla‐Parra, S. (2020) · Viruses · doi:10.3390/v12020206 · Cited by 15
“Immediately following addition of virus harboring Vpr-BlaM, cells were placed at 4 ◦C for 1 h. Viral inoculum was then removed and cells were washed with PBS 1X to remove unbound viruses before replacing the medium with 100 µL of complete DMEM.”
MethodInfluentialMembrane Protein OTOF Is a Type I Interferon-Induced Entry Inhibitor of HIV-1 in Macrophages
Ding, H., Zhang, X., Zhu, Z., Wang, S., Xiong, Y., Shang, H., & Liang, G. (2022) · mBio · doi:10.1128/mbio.01738-22 · Cited by 16
Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins
Dobrowsky, T. M., Rabi, S. A., Nedellec, R., Daniels, B. R., Mullins, J. I., Mosier, D. E., Siliciano, R. F., & Wirtz, D. (2013) · Scientific Reports · doi:10.1038/srep03014 · Cited by 15
On chip electrochemical detection of sarcoma protein kinase and HIV-1 reverse transcriptase
Martić, S., Labib, M., & Kraatz, H. (2011) · Talanta · doi:10.1016/j.talanta.2011.07.090 · Cited by 15
Viral Transduction Enhancing Effect of EF‐C Peptide Nanofibrils Is Mediated by Cellular Protrusions
Schütz, D., Rode, S., Read, C., Müller, J. A., Glocker, B., Sparrer, K. M. J., Fackler, O., Walther, P., & Münch, J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104814 · Cited by 15
Cavrois, M., Hilton, J. F., Roan, N. R., Takeda, M., Seidman, D. L., Averbach, S., Chang, E., Raman, N., Greenblatt, R. M., Shacklett, B. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221181 · Cited by 14
Self-citationPermanyer, M., Ballana, E., Badía, R., Pauls, E., Clotet, B., & Esté, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.343293 · Cited by 14
“Virus-Cell Fusion Assay—The quantification of the virus-cell membrane fusion was quantified as described before (30).”
MethodFeo, C. J. D., Wang, W., Hsieh, M., Zhuang, M., Vassell, R. A., & Weiss, C. D. (2014) · Retrovirology · doi:10.1186/preaccept-1715264856128511 · Cited by 14
Galiwango, R. M., Yegorov, S., Joag, V., Prodger, J. L., Shahabi, K., Huibner, S., Muyanja, E., Kabuubi, B. R., Namuniina, A., Nalutaaya, A., et al. (2019) · American Journal of Reproductive Immunology · doi:10.1111/aji.13143 · Cited by 14
Les IFITM, un obstacle commun à de nombreux virus
Tartour, K., & Cimarelli, A. (2015) · médecine/sciences · doi:10.1051/medsci/20153104011 · Cited by 14
Mlčochová, P., Watters, S. A., Towers, G. J., Noursadeghi, M., & Gupta, R. K. (2014) · Retrovirology · doi:10.1186/1742-4690-11-25 · Cited by 13
“We demonstrate that the block to infection in macrophages is sensitive to CD4 cell surface levels using Affinofile cells [31].”
MethodQuantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test
Roessler, J., Pich, D., Albanese, M., Wratil, P. R., Krähling, V., Hellmuth, J. C., Scherer, C., von Bergwelt‐Baildon, M., Becker, S., Keppler, O. T., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac045 · Cited by 16
Tilton, C. A., Tabler, C. O., Lucera, M. B., Marek, S. L., Haqqani, A. A., & Tilton, J. C. (2013) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.08.029 · Cited by 14
“Briefly, packaging cells were transfected with plasmids encoding β-lactamase–vpr (bla-vpr) (Cavrois et al., 2002), HIV envs with known coreceptor tropism, and an NL4-3 env- HIV genome containing an egfp-env chimeric gene under control of the viral LTR promoter (Zhang et al., 2004).”
MethodLu, W., Chen, S., Yu, J., Behrens, R. T., Wiggins, J., Sherer, N. M., Liu, S., Xiong, Y., Xiang, S.-H., & Wu, L. J. (2019) · Journal of Virology · doi:10.1128/jvi.02128-18 · Cited by 13
“A fusion assay using beta-lactamase-Vpr (BlaM-Vpr) was performed as previously described with modifications (14, 16).”
MethodMüller, J. A., Glöckle, A., Gawanbacht, A., Geyer, M., Münch, J., & Kirchhoff, F. (2018) · Journal of Virology · doi:10.1128/jvi.00733-18 · Cited by 13
“pCMV_BlaM_Vpr and pAdVAntage were used to generate -lactamase incorporating viruses as described previously (21).”
MethodWiredja, D. D., Tabler, C. O., Schlatzer, D., Li, M., Chance, M. R., & Tilton, J. C. (2018) · Retrovirology · doi:10.1186/s12977-018-0423-4 · Cited by 15
“2247 [65] and a β-lactamase-Vpr fusion protein [40, 41].”
In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2
Hoffmann, M. A. G., Kieffer, C., & Björkman, P. J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.003 · Cited by 12
“17 Whereas viral entry events were % 0.3% in control RBCs and CD4-RBCs, entry was detected in 6.1% of CD4-CCR5-RBCs, suggesting that RBC viral traps that present both receptors can entrap the virus.”
InfluentialDey, S., Pahari, P., Mukherjee, S., Munro, J. B., & Das, D. K. (2024) · Structure · doi:10.1016/j.str.2024.09.008 · Cited by 13
α-Synuclein fibrils enhance HIV-1 infection of human T cells, macrophages and microglia
Olari, L., Liu, S., Arnold, F., Kühlwein, J., Miró, M. G., Updahaya, A. R., Stürzel, C. M., Thal, D. R., Walther, P., Sparrer, K. M. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56099-z · Cited by 12
Trifkovic, S., Gilbertson, B. P., Fairmaid, E. J., Cobbin, J. C. A., Rockman, S. P., & Brown, L. E. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.683152 · Cited by 12
Strategic self-limiting production of infectious HIV particles by CRISPR in permissive cells
Liu, H., Chen, C., Liao, S., Sohai, D. K., Cruz, C. C., Burdo, T. H., Cradick, T. J., Mehta, A. S., Barrero, C. A., Florez, M. L., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.027 · Cited by 12
“To further investigate the viral entry step, we performed a sensitive and specific enzyme-based assay allowing quantitative measurement of virion entry by fusion, Vpr-b-lactamase assay.(23) In this assay b-lactamase-Vpr chimeric proteins (BlaM-Vpr) are incorporated during packaging into HIV-1 virions and subsequently…”
MethodCIB1 and CIB2 are HIV-1 helper factors involved in viral entry
Godinho‐Santos, A., Hance, A. J., Gonçalves, J., & Mammano, F. (2016) · Scientific Reports · doi:10.1038/srep30927 · Cited by 14
Galiwango, R. M., Bagaya, B. S., Mpendo, J., Joag, V., Okech, B. A., Nanvubya, A., Ssetaala, A., Muwanga, M., & Kaul, R. (2019) · Trials · doi:10.1186/s13063-019-3545-7 · Cited by 12
A novel small-molecule inhibitor of HIV-1 entry
de Leeuw, E., Heredia, A., Latinovic, O., & Barbault, F. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s89338 · Cited by 11
“To examine if 5660386 inhibits viral entry directly, we measured inhibition of replication-incompetent CCR5-and CXCR4-dependent viruses by BlaM fusion assay 52 (Figure 5).”
Differential Inhibition of HIV Replication by the 12 Interferon Alpha Subtypes
Tauzin, A., Ortiz, A. E., Blake, O., Soundaramourty, C., Joly-Beauparlant, C., Nicolas, A., Droit, A., Dutrieux, J., Estaquier, J., & Mammano, F. (2021) · Journal of Virology · doi:10.1128/jvi.02311-20 · Cited by 12
“We thus measured the inhibition on individual steps, starting with virus entry, the efficiency of which can be evaluated by the Vpr–b-lactamase (BLaM) assay (37).”
MethodMalinowsky, K., Luksza, J., & Dittmar, M. T. (2008) · Virology · doi:10.1016/j.virol.2008.02.034 · Cited by 11
“24hpost transfection cellswere infectedwith thepseudotypedvirions for 4 h, and subsequently stained with CCF2 as described (Cavrois et al., 2002).”
MethodFromentin, R., Tardif, M. R., & Tremblay, M. J. (2010) · Journal of General Virology · doi:10.1099/vir.0.028746-0 · Cited by 11
“The fusion assay was performed by a method described previously by Cavrois et al. (2002).”
MethodRole of Ezrin Phosphorylation in HIV-1 Replication
Kamiyama, H., Izumida, M., Umemura, Y., Hayashi, H., Matsuyama, T., & Kubo, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01912 · Cited by 11
“Virus-Cell Membrane Fusion Activity Virus-cell membrane fusion activity was measured as previously reported (Cavrois et al., 2002).”
MethodMARCH2, a T cell specific factor that restricts HIV-1 infection
Umthong, S., Timilsina, U., D’Angelo, M. R., Salka, K., & Stavrou, S. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012330 · Cited by 10
“Virion fusion assays were performed as previously described [31,71].”
BackgroundMethodNzounza, P., Chazal, M., Guedj, C., Schmitt, A., Massé, J., Randriamampita, C., Pique, C., & Ramírez, B. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030130 · Cited by 10
Tsibris, A. M. N., Hu, Z., Paredes, R., Leopold, K. E., Putcharoen, O., Schure, A. L., Mazur, N., Coakley, E. P. G., Su, Z., Gulick, R. M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00286-12 · Cited by 10
Gonzalez, G., DaFonseca, S., Errazuriz-Cerda, E., Coric, P., Souquet, F., Turcaud, S., Boulanger, P. A., Bouaziz, S., & Hong, S. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027234 · Cited by 11
“. The β-lactamase-Vpr construct was the first fusion protein used to develop a sensitive Vpr-enzyme based assay to monitor a specific step of the HIV-1 infection cycle, the HIV-1-host cell fusion and entry”
MethodPermanyer, M., Pauls, E., Badía, R., Esté, J. A., & Ballana, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079221 · Cited by 10
Fleta-Soriano, E., Smutná, K. F., Martínez, J. P., Lorca-Oró, C., Sadiq, S. K., Mirambeau, G., López‐Iglesias, C., Bosch, M., Pol, A., Brönstrup, M., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00739-17 · Cited by 9
“Samples were incubated overnight, analyzed by flow cytometry, and used to estimate fusion capacity as described previously (19).”
MethodIL-2 Inducible Kinase ITK is Critical for HIV-1 Infection of Jurkat T-cells
Hain, A., Krämer, M., Linka, R. M., Nakhaei‐Rad, S., Ahmadian, M. R., Häussinger, D., Borkhardt, A., & Münk, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-21344-7 · Cited by 9
Fusogenic structural changes in arenavirus glycoproteins are associated with viroporin activity
Zhang, Y., York, J., Brindley, M. A., Nunberg, J. H., & Melikyan, G. B. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011217 · Cited by 10
“To produce LASV pseudoviruses carrying β-lactamase-Vpr (BlaM-Vpr) for a bulk virus-cell fusion assay [46,47], HEK293T/17 cells were transfected with wild-type or mutant LASV-GPc, pR9ΔEnv, BlaM-Vpr and pcRev plasmids.”
MethodMeasuring HIV fusion mediated by envelopes from primary viral isolates
Cavrois, M., Neidleman, J. A., Galloway, N. L. K., Derdeyn, C. A., Hunter, E., & Greene, W. C. (2010) · Methods · doi:10.1016/j.ymeth.2010.05.010 · Cited by 9
“The virion-based fusion assay has been previously described in considerable detail [28, 29].”
MethodSelf-citationA reason to be optimistic about biodiesel: seed meal as a valuable soil amendment
Cohen, M. F., & Mazzola, M. (2004) · Trends in biotechnology · doi:10.1016/s0167-7799(04)00075-7 · Cited by 9
Albanese, M., Chen, H., Gapp, M., Muenchhoff, M., Yang, H.-H., Peterhoff, D., Hoffmann, K., Xiao, Q., Ruhle, A., Ambiel, I., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101483 · Cited by 8
Anatomical, subset, and HIV-dependent expression of viral sensors and restriction factors
George, A. F., Neidleman, J. A., Luo, X., Frouard, J., Elphick, N., Yin, K., Young, K. C., Ma, T., Andrew, A. K., Ezeonwumelu, I. J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115202 · Cited by 8
“We first implemented an HIV fusion assay 68 to determine the intracellular VISOR landscape of HIV-infected cells during the earliest stage (viral entry) of the HIV replication cycle.”
Tan, T. S., Toyoda, M., Tokunaga, K., & Ueno, T. (2021) · Journal of Virology · doi:10.1128/jvi.00634-21 · Cited by 9
“We tested the panel of SERINC5 mutants at position 412 for the viruscell fusion process by using the BlaM-Vpr fusion assay (21).”
MethodVilmen, G., Smith, A. C., Cervera, H., Shukla, R. K., Larue, R. C., Herschhorn, A., & Sharma, A. (2022) · mBio · doi:10.1128/mbio.02752-21 · Cited by 8
Marmé, N., Knemeyer, J., Wolfrum, J., & Sauer, M. (2004) · Angewandte Chemie · doi:10.1002/ange.200453835 · Cited by 8
Guizar, P., Abdalla, A. L., Monette, A., Davis, K., Caballero, R. E., Niu, M., Liu, X., Ajibola, O., Murooka, T. T., Chen, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110131 · Cited by 8
“To test this, we performed the b -lactamase (BlaM) activity assay, 65 and show that PICALM KO cells displayed reduced viral fusion efficiencies comparedtoWTcells (Figures3Aand3B; FiguresS6AandS6B).”
Human Immunodeficiency Viruses: Propagation, Quantification, and Storage
Peters, P. J., Richards, K. H., & Clapham, P. R. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc15j01s28 · Cited by 7
Esposito, A. M., Soare, A. Y., Patel, F., Satija, N., Chen, B. K., & Swartz, T. H. (2018) · Journal of Visualized Experiments · doi:10.3791/58074 · Cited by 7
Measuring the subcellular compartmentalization of viral infections by protein complementation assay
Fernandez, J., Hassen‐Khodja, C., Georget, V., Rose, T., Jacob, Y., Janin, Y. L., Nisole, S., Vidalain, P., & Arhel, N. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010524118 · Cited by 7
A Conserved Tryptophan in the Envelope Cytoplasmic Tail Regulates HIV-1 Assembly and Spread
Snetkov, X., Haider, T., Mesner, D., Groves, N. S., van Engelenburg, S. B., & Jolly, C. L. (2022) · Viruses · doi:10.3390/v14010129 · Cited by 8
“To test whether W757 was fusion-competent, the BlaM-Vpr fusion assay was used to measure the capacity of Env W757A virions to fuse with target cells, resulting in BlaM-Vpr release into the target cell and cleavage of CCF2 [37].”
MethodSystematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cells
Rathore, U., Dugan, E. J., Thornton, H., Kumar, V. E., Dajani, R., Burdick, R. C., Young, J. M., Steinhart, Z., Lao, R., Delviks‐Frankenberry, K. A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.046 · Cited by 6
Macropinosomes are a site of HIV-1 entry into primary CD4 + T cells
Murakami, T., Cardoso, R. D. S., Manivannan, P., Chang, Y.-T., Rentchler, E. C., Chou, K.-N., Tang, Y., Swanson, J. A., King, P. D., & Ono, A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417676122 · Cited by 6
“To test whether EIPA prevents cytoplasmic HIV - 1 entry, we performed the BlaM - Vpr - based fusion assay (36), which measures the amount of virion - incorporated BlaM - Vpr released into the cytosol upon HIV - 1 fusion with target cells.”
Modulation of the functional interfaces between retroviral intasomes and the human nucleosome
Mauro, E., Lapaillerie, D., Tumiotto, C., Charlier, C., Martins, F. G., Sousa, S. F., Métifiot, M., Weigel, P., Yamatsugu, K., Kanai, M., et al. (2023) · mBio · doi:10.1128/mbio.01083-23 · Cited by 6
“Measurement of virus cell fusion efficiency was performed using chimeric viruses containing a Vpr protein fused with the β-lactamase (Vpr-BLaM) (40).”
MethodMarmé, N., Weston, K. D., Staudt, T., Spatz, J. P., & Knemeyer, J. (2005) · International Journal of Environmental & Analytical Chemistry · doi:10.1080/03067310500147720 · Cited by 6
Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors
Giroud, C., Du, Y., Marin, M., Min, Q., Jui, N. T., Fu, H., & Melikyan, G. B. (2017) · Assay and Drug Development Technologies · doi:10.1089/adt.2017.777 · Cited by 6
“incorporate the beta-lactamase enzyme into HIV-1 pseudoviruses using the BlaM-Vpr chimera.(30) The BlaM activity in the cytoplasm that results from the virus–cell fusion is”
MethodHoward, A. R., & Munro, J. B. (2019) · Advances in virus research · doi:10.1016/bs.aivir.2019.05.004 · Cited by 6
“Many well-known virology techniques, such as the β-lactamase (BlaM) assay for virus entry (Cavrois et al., 2002; Dale et al., 2011; Jones and Padilla-Parra, 2016; Marin et al., 2015), and some viral fusion and lipid mixing assays (Struck et al.”
MethodLFA1 and ICAM1 are critical for fusion and spread of murine leukemia virus in vivo
Engels, R., Falk, L., Albanese, M., Keppler, O. T., & Sewald, X. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110279 · Cited by 7
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
Latinovic, O., Schneider, K., Szmacinski, H., Lakowicz, J. R., Heredia, A., & Redfield, R. R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.10.006 · Cited by 5
“We first measured viral entry inhibition by FLSC IgG1 versus FLSC in JC clones expressing two different CCR5 levels (JC53 = 50,000 molecules/cell and JC57 = 9,000 molecules/cell) using the BlaM fusion assay (Cavrois et al., 2002).”
MethodFrom Virus-like Particles to Engineered Exosomes for a New Generation of Vaccines
Federico, M. (2012) · Future Virology · doi:10.2217/fvl.12.29 · Cited by 5
“In particular, Vpr has been reported to incorporate at basically unchanged levels when either CAT [34], GFP [35] or b-lactamase [36] are fused at its N-terminus.”
BackgroundCadima-Couto, Í., Tauzin, A., Freire, J. M., Figueira, T. N., Silva, R. D. M., Pérez‐Peinado, C., Cunha-Santos, C., Bártolo, I., Taveira, N., Gano, L., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00507 · Cited by 5
Aguilera, J., & Sun, J. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3991 · Cited by 4
“Keywords: CCF4-AM, Mycobacterium marinum, EsxA, EsxB, FRET [Background] The development of a β-lactamase reporter assay gave rise to the subsequent Förster resonance energy transfer (FRET) assay (Zlokarnik et al., 1998; Cavrois et al., 2002).”
MethodImamichi, T., Chen, Q., Sowrirajan, B., Yang, J., Laverdure, S., Marquez, M., Mele, A. R., Watkins, C., Adelsberger, J. W., Higgins, J. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287829 · Cited by 4
“The HIV-1 NL4/3 -Env AD.8 - Δ Vpr with Vpr-BLAM was produced by transfection of pHIV-1 NL4/3 -Env AD.8 - Δ Vpr and pVpr-BLAM [54, 55] (a kind gift from Dr. Warner Greene) into HEK293T cells.”
Cronin, S., de Vries-Egan, A., Vahlas, Z., Czernikier, A., Melucci, C., Gerber, P. P., O’Neil, T. R., Gloss, B., Sharabas, M., Turk, G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110324 · Cited by 4
“33,34 A shift in the CCF2 fluorescence emission spectrum from 520 nm to 447 nm indicates the enzymatic cleavage of CCF2 by Vpr-BlaM and therefore viral fusion with the plasma membrane of CD4 + T cells.”
Cadena-Cruz, C., De-Ávila-Arias, M., Costello, H. M., Hurtado-Gómez, L., de la Rosa, W. Á. M., Macchia-Ceballos, G., Rosales, W., Valencia-Villa, G., Villalba, P., Kararoudi, M. N., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1498955 · Cited by 4
“Recombinant HIV-1 virions carrying BlaM-Vpr, designed by Cavrois et al. (2002), contributed to understanding how HIV-1 enters target cells and to identifying a set of molecules important for viral entry (Miyauchi et al., 2009; Herold et al., 2014; Putcharoen et al., 2012; Durham and Chen, 2016;…”
Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein
Joshi, V. R., Newman, R. M., Pack, M. L., Power, K. A., Munro, J. B., Okawa, K., Madani, N., Sodroski, J., Schmidt, A. G., & Allen, T. M. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008577 · Cited by 4
“To explore this hypothesis, we tested virus-cell fusion using the βlactamase–Vpr (Blam-Vpr) assay [36].”
MethodMhlekude, B., Lenman, A., Sidoyi, P., Joseph, J. T., Kruppa, J., Businge, C. B., Mdaka, M. L., Konietschke, F., Pich, A., Gerold, G., et al. (2021) · AIDS · doi:10.1097/qad.0000000000003003 · Cited by 4
“3 (60 mg), pBlaM (20 mg) and pAdvantage (8 mg) [27,28].”
Time‐resolved single virus tracking and spectral imaging to understand HIV‐1 entry and fusion
Padilla‐Parra, S. (2022) · Biology of the Cell · doi:10.1111/boc.202200082 · Cited by 4
“Also, SVT and different functional assays (time-of-addition beta-lactamase assay (CarlonAndres & Padilla-Parra, 2020; Cavrois et al., 2002; Jones & Padilla-Parra 2016) showed the importance of dynamin and endocytosis during HIV-1 fusion.”
Method
Metadata
- Authors
- Cavrois, M., de Noronha, C., & Greene, W. C.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Greene, Warner C.
- Venue
- Nature Biotechnology
- Published
- 2002-09-30
- Volume
- 20
- Issue
- 11
- Pages
- 1151-1154
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2029379203
- Cited by
- 475
- References
- 16
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 19 · 2021: 24 · 2020: 22 · 2019: 25 · 2018: 20 · 2017: 31 · 2016: 16 · 2015: 27 · 2014: 28 · 2013: 22 · 2012: 31
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01 HD40543, P01HD040543)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1, viral entry, fluorescent substrate, HIV-1 envelope
- MeSH terms
- Cell Fusion, Humans, Immunoenzyme Techniques, Membrane Fusion, Sensitivity and Specificity, T-Lymphocytes, Tumor Cells, Cultured, Viral Fusion Proteins, Virion, Reproducibility of Results, HIV-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.